| DC60635 |
DS18
Featured
|
DS18 is a DDB1-CDK12 molecular glue with EC50 of 8.771 nM. |
|
| DC66588 |
GlyRS-IN-1
Featured
|
GlyRS-IN-1 is a glycyl-tRNA synthase (GlyRS) inhibitor extracted from patent WO 2017066459 A1. GlyRS-IN-1 can also inhibit the growth of bacteria. |
|
| DC66589 |
1,4,7,10-Tetraoxa-13,16-diazacyclooctadecane
Featured
|
|
|
| DC66590 |
3-Pyrrolidinol, 5-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-, hydrochloride (1:1), (3S,5R)-
Featured
|
|
|
| DC66591 |
5-bromo-1H-pyrrolo[2,3-b]pyridine-2,3-dione
Featured
|
|
|
| DC66592 |
GW274150 dihydrochloride
Featured
|
GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation. |
|
| DC66593 |
HP-NH2
Featured
|
|
|
| DC66594 |
AJ-76
Featured
|
AJ-76 ((+)-AJ 76; (1S,2R)-AJ 76) is a dopamine autoreceptor antagonist. AJ-76 can increase the synthesis and turnover of dopamine in the rat brain, while having little effect on the synthesis and turnover of serotonin (5-HT) and norepinephrine. AJ-76 can also antagonize the sedative effects of low-dose apomorphine and has a weak antagonistic effect on postsynaptic dopamine receptor. |
|
| DC66595 |
(+)-UH 232
Featured
|
(+)-UH 232 is a partially selective agonist of the D3 receptor with an intrinsic activity of 0.2-0.4. (+)-UH 232 antagonized quinpirole-induced mitogenesis with a Ki value of 9.4 nM. |
|
| DC66596 |
Bartsiosid
Featured
|
Bartsioside is an anti-inflammatory agent which can be extracted from C. deserticola. Bartsioside exerts no significant cytotoxicity under 40 μM to BV-2 cells. |
|
| DC66597 |
1-O-palmityl-D-glucuronic acid
Featured
|
|
|
| DC66598 |
Octadecyl β-D-glucopyranosiduronic acid
Featured
|
|
|
| DC66599 |
β-D-Glucopyranosiduronic acid, tetradecyl
Featured
|
|
|
| DC66600 |
BLU-222
Featured
|
BLU-222 is an investigational, oral, potent, and selective CDK2 inhibitor. BLU-222 has shown robust anti-tumor activity in preclinical models of CCNE-aberrant ovarian, breast and gastric cancer. |
|
| DC66601 |
Zoniporide
Featured
|
|
|
| DC66602 |
Gepotidacin mesylate
Featured
|
Gepotidacin, also known as GSK-2140944, is a potent Type II DNA topoisomerase inhibitor. Gepotidacin is a novel antibacterial drug candidate. Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively. |
|
| DC66603 |
IWY357
Featured
|
|
|
| DC66604 |
EOS-984
Featured
|
|
|
| DC66605 |
NDI-101150
Featured
|
NDI-101150 is a highly selective, orally bioavailable small-molecule inhibitor targeting hematopoietic progenitor kinase 1 (HPK1/MAP4K1), a key negative regulator of T-cell signaling. This compound demonstrates potent immunomodulatory activity by enhancing T-cell activation and proliferation, while simultaneously exhibiting robust antitumor efficacy in preclinical models. Its mechanism of action involves disrupting HPK1-mediated suppression of immune responses, leading to improved T-cell function and sustained inhibition of tumor progression. With its favorable pharmacokinetic profile and specificity for HPK1, NDI-101150 represents a promising therapeutic candidate for cancer immunotherapy, particularly in settings where T-cell activity is compromised. |
|
| DC66606 |
TYRA-300
Featured
|
TYRA-300 is the first oral selective FGFR3 inhibitor with IC50 of 11 nM in Ba/F3 cells, and shows selectivity over FGFR1, FGFR2 and FGFR4 in Ba/F3 cells was 25-, 14-, and 36-fold, respectively. TYRA-300 demonstrates equivalent potency for FGFR3 WT and V555M/L gatekeeper mutations in enzymatic assays and in engineered RT112/84 and UM-UC-14 bladder cancer cell lines containing the V555M mutation. |
|
| DC66607 |
BAY2925976
Featured
|
|
|
| DC66608 |
BMS-986397
Featured
|
|
|
| DC66609 |
PLX-4545
Featured
|
|
|
| DC66610 |
Castadifan
Featured
|
|
|
| DC66611 |
PF-07328948
Featured
|
PF-07328948 is an orally bioavailable small-molecule inhibitor targeting branched-chain ketoacid dehydrogenase kinase (BDK), exhibiting an IC50 of 110 nM. By selectively antagonizing BDK activity, this compound prevents phosphorylation-mediated suppression of the branched-chain ketoacid dehydrogenase (BCKDH) enzyme complex, thereby reactivating BCKDH-dependent catabolism of branched-chain amino acids (BCAAs). Preclinical studies in rodent models have demonstrated its ability to improve metabolic dysfunction and pathological markers linked to heart failure, highlighting its therapeutic potential for modulating energy homeostasis and cardiac performance. |
|
| DC66612 |
VVD-130037
Featured
|
VVD-130037 is an oral covalent activator of KEAP/NRF2 degrader. |
|
| DC66613 |
BMS-986308
Featured
|
BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research. |
|
| DC60636 |
Acid-degradable Cationic Lipid (ADC)
Featured
|
Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo. |
.png)
|
| DC60637 |
BI-9508
Featured
|
BI-9508 is a potent and selective, brain-penetrant GPR88 agonist with EC50 of 47 nM. |
|
| DC66614 |
Vc-seco-duba
Featured
|
Vc-seco-DUBA (SYD985) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco. |
|
